GALNT13 antisense RNA 1 (GALNT13-AS1)

GALNT13 antisense RNA 1 (GALNT13-AS1) is a long noncoding RNA transcribed from the strand antisense to the GALNT13 gene on human chromosome 2[1][9][8]. As a member of the natural antisense transcripts (NATs), the general function of such RNAs is to regulate the expression of their associated sense gene through mechanisms such as transcriptional interference, RNA-RNA interactions, modulation of epigenetic state, or posttranscriptional regulation[3]. Antisense RNAs may act in cis (locally on the same chromosome) or in trans (at distant sites), often affecting the expression, stability, or translation of the corresponding sense gene mRNA[3]. However, there are no current publications directly linking GALNT13-AS1 to a specific disease, drug interaction, or direct therapeutic targeting based on available data[1][8][9]. Key points: - GALNT13-AS1 is distinct from GALNT13 (the enzyme polypeptide N-acetylgalactosaminyltransferase 13); all major disease and therapy reports focus on GALNT13, not its antisense RNA[2][4][7][10]. - There are no genome-wide association studies, biomarkers, or interacting drugs specifically reported for GALNT13-AS1 as of the latest search[8]. - Not considered a therapeutic target, enzyme, receptor, or transporter; its main relevance is regulatory, consistent with general NAT functions[3]. - No evidence or claim that the target is misspelled or conceptually incorrect in this context. If more data emerges about GALNT13-AS1's precise biological role or disease relevance, additional categories can be updated. At present, it is best classified as a regulatory noncoding transcript rather than a therapeutically actionable molecular target.

Other names

AC009227.1GALNT13-AS1